COSMO Pharmaceuticals N.V. (CH:COPN)
:COPN
Want to see CH:COPN full AI Analyst Report?
Top Page
COSMO Pharmaceuticals N.V.
(COPN)
Select Model
Select Model
Rating:49Neutral
Price Target:
CHF67.00
▼(-31.49% Downside)
Action:Reiterated
Date:03/12/26
The score is driven primarily by unstable operating results and a sharp 2025 deterioration in profitability and cash generation, despite a very strong, low-leverage balance sheet. Weak technical momentum adds near-term risk, while valuation is constrained by negative earnings with only modest support from the ~2% dividend yield.
Positive Factors
Balance-sheet strength
Very low leverage and substantial equity provide durable financial flexibility. This allows the company to fund R&D, support commercialization or partner negotiations, and withstand temporary cash shortfalls without immediate refinancing pressure, improving long-term resilience.
Negative Factors
Sharp 2025 revenue and margin decline
A large, persistent drop in revenue and shift to negative margins reduces scale benefits and undermines the company's ability to cover fixed costs and sustain investments. This structural decline weakens long-term earnings visibility and strains partner and customer relationships.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance-sheet strength
Very low leverage and substantial equity provide durable financial flexibility. This allows the company to fund R&D, support commercialization or partner negotiations, and withstand temporary cash shortfalls without immediate refinancing pressure, improving long-term resilience.
Read all positive factors
COSMO Pharmaceuticals N.V. (COPN) vs. iShares MSCI Switzerland ETF (EWL)
Market Cap
CHF1.11B
Dividend Yield1.82%
Average Volume (3M)19.52K
Price to Earnings (P/E)―
Beta (1Y)1.17
Revenue Growth-61.60%
EPS Growth-102.68%
CountryCH
Employees325
SectorGeneral
Sector StrengthN/A
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)-0.23
Shares Outstanding17,543,522
10 Day Avg. Volume18,700
30 Day Avg. Volume19,520
Financial Highlights & Ratios
PEG Ratio4.78
Price to Book (P/B)3.74
Price to Sales (P/S)17.21
P/FCF Ratio-113.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF145.00Price Target Upside48.26% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.1
Revenue Forecast (FY)CHF106.30M
COSMO Pharmaceuticals N.V. Business Overview & Revenue Model
Company Description
Cosmo Pharmaceuticals NV engages in the development and manufacture of treatments and products for gastrointestinal diseases and dermatology. Its products include Lialda/Mezavant/Mesavancol, Uceris/Cortiment, Winlevi, GI Genius, Lumeblue, Aemcolo/...
How the Company Makes Money
Cosmo generates revenue primarily through (1) sales of its own commercialized products and (2) partnering/licensing arrangements in which other pharmaceutical companies commercialize Cosmo-originated products in specific territories or indications...
COSMO Pharmaceuticals N.V. Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
86
Very Positive
Cash Flow
33
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 104.85M | 266.79M | 92.78M | 102.09M | 65.07M |
| Gross Profit | 48.78M | 246.92M | 53.44M | 83.33M | 49.93M |
| EBITDA | 2.36M | 165.71M | 19.70M | 46.74M | 17.81M |
| Net Income | -3.63M | 133.24M | -4.93M | 17.23M | 21.67M |
Balance Sheet | |||||
| Total Assets | 612.16M | 646.77M | 553.98M | 759.59M | 805.56M |
| Cash, Cash Equivalents and Short-Term Investments | 122.66M | 142.96M | 50.27M | 240.95M | 222.21M |
| Total Debt | 4.26M | 2.20M | 1.84M | 173.60M | 169.92M |
| Total Liabilities | 123.36M | 141.68M | 124.94M | 295.80M | 292.88M |
| Stockholders Equity | 481.92M | 498.33M | 422.16M | 456.93M | 505.28M |
Cash Flow | |||||
| Free Cash Flow | -15.85M | 156.76M | 18.31M | 25.92M | 4.11M |
| Operating Cash Flow | -11.62M | 162.41M | 22.71M | 33.23M | 12.61M |
| Investing Cash Flow | 49.85M | -128.88M | 42.30M | 1.69M | 24.86M |
| Financing Cash Flow | -24.61M | -40.22M | -211.27M | -46.13M | -27.25M |
COSMO Pharmaceuticals N.V. Technical Analysis
Negative
97.80
Price Trends
77.68
Negative
88.27
Negative
83.64
Negative
Market Momentum
-3.01
Negative
33.48
Neutral
18.46
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:COPN, the sentiment is Negative. The current price of 97.8 is above the 20-day moving average (MA) of 69.81, above the 50-day MA of 77.68, and above the 200-day MA of 83.64, indicating a bearish trend. The MACD of -3.01 indicates Negative momentum. The RSI at 33.48 is Neutral, neither overbought nor oversold. The STOCH value of 18.46 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CH:COPN.
COSMO Pharmaceuticals N.V. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | CHF637.71M | 19.58 | ― | ― | 11.43% | -48.80% | |
56 Neutral | CHF720.95M | 429.11 | -7.82% | ― | 59.85% | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
52 Neutral | CHF325.97M | 49.31 | ― | 4.54% | -7.42% | ― | |
51 Neutral | CHF1.10B | 120.00 | ― | ― | 19.76% | 150.73% | |
49 Neutral | CHF1.11B | -310.56 | 11.46% | 1.82% | -61.60% | -102.68% |
* General Sector Average
CH:COPN
COSMO Pharmaceuticals N.V.
65.90
10.16
18.23%
CH:BSLN
Basilea Pharmaceutica
51.90
4.30
9.03%
CH:KURN
Kuros Biosciences
18.28
-9.90
-35.13%
CH:MEDX
medmix AG
7.90
-3.57
-31.14%
CH:MED
Medartis Holding AG
80.40
2.60
3.34%
COSMO Pharmaceuticals N.V. Corporate Events
Cosmo accelerates European rollout of first-in-class acne drug Winlevi
Jun 15, 2026
Cosmo Pharmaceuticals has expanded the European rollout of its acne treatment Winlevi, with market launches in Austria and Germany via distribution partner InfectoPharm, following EU approval in late 2025. As exclusive manufacturer, Cosmo is prepa...
Cosmo and Glenmark roll out first-in-class acne drug Winlevi across key European markets
Jun 11, 2026
Cosmo Pharmaceuticals’ dermatology unit Cassiopea has developed Winlevi, a first-in-class topical acne therapy based on the androgen receptor inhibitor clascoterone, and retains European rights while Cosmo serves as exclusive manufacturer. T...
Cosmo completes Phase II recruitment for novel ulcerative colitis therapy
May 18, 2026
Cosmo Pharmaceuticals has completed patient recruitment for a Phase II trial of its Rifamycin enema, an investigational treatment for distal ulcerative colitis and ulcerative proctitis, enrolling 77 patients across 24 European sites. The study wil...
Cosmo’s Clascoterone Delivers Strong 12‑Month Data in Male Hair Loss, Paving Way for 2027 Filings
Apr 15, 2026
Cosmo Pharmaceuticals has reported positive 12‑month Phase III data for its Clascoterone 5% topical solution in men with mild to moderate androgenetic alopecia, showing a safety profile comparable to placebo over a year and no significant sy...
Cosmo Shareholders Approve All AGM Resolutions and EUR 2.10 Dividend
Apr 10, 2026
Cosmo Pharmaceuticals reported that shareholders approved all agenda items at the 2026 Annual General Meeting, with 59.02% of outstanding ordinary shares represented. Investors backed a dividend of EUR 2.10 per share, with the ex-dividend date set...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.